Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

48.39
-1.4300-2.87%
Volume:15.08M
Turnover:730.88M
Market Cap:98.46B
PE:-10.96
High:49.33
Open:47.63
Low:47.61
Close:49.82
Loading ...

Top Research Reports for Exxon Mobil, Bristol-Myers Squibb & Chubb

Zacks
·
03 Apr

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Zacks
·
03 Apr

Drug Industry Offers Tepid Pushback to Kennedy's FDA Job Cuts -- Barrons.com

Dow Jones
·
02 Apr

Is Bristol Myers Squibb's High-Yielding Dividend Safe?

Motley Fool
·
02 Apr

RBC Canadian Equity Income Fund's Strategic Move: Alimentation Couche-Tard Inc. Takes Center Stage

GuruFocus.com
·
02 Apr

Bristol Myers Squibb Co. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
02 Apr

The FDA Is 'Finished' as Firings Sweep Health Agencies. Drug Stocks Are Falling. -- Barrons.com

Dow Jones
·
02 Apr

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Zacks
·
02 Apr

Is Bristol-Myers Squibb (BMY) One of the Best Healthcare Stocks to Buy According to Billionaires?

Insider Monkey
·
01 Apr

Beat the S&P 500 With This Cash-Gushing Dividend Stock

Motley Fool
·
01 Apr

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
01 Apr

Bristol-Myers Squibb Company (BMY): Among the Best High Yield Stocks to Buy in April for Dividend Capture

Insider Monkey
·
01 Apr

Jim Cramer on Bristol-Myers Squibb. Co (NYSE:BMY): They Should Have Known Better

Insider Monkey
·
29 Mar

Trump nominees disclose US law firm pay

Reuters
·
29 Mar

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
29 Mar

Bristol-Myers Squibb (NYSE:BMY) Sees Rising Interest in Sotyktu Despite 3% Share Price Dip

Simply Wall St.
·
29 Mar

BRIEF-Bristol Myers Squibb Receives Positive CHMP Opinion For The Subcutaneous Formulation Of Opdivo® (Nivolumab) Across Multiple Solid Tumor Indications

Reuters
·
28 Mar

Bristol Myers Gets CHMP Backing for Subcutaneous Opdivo

Dow Jones
·
28 Mar

Bristol Myers Squibb Receives Positive Chmp Opinion for the Subcutaneous Formulation of Opdivo® (Nivolumab) Across Multiple Solid Tumor Indications

THOMSON REUTERS
·
28 Mar

Bristol-Myers Squibb Co - EU Decision on Opdivo Marketing Authorization Expected by June 2, 2025

THOMSON REUTERS
·
28 Mar